8.92
+4.23(+90.19%)
Currency In USD
Previous Close | 4.69 |
Open | 4.8 |
Day High | 12.32 |
Day Low | 4.71 |
52-Week High | 19.71 |
52-Week Low | 2.21 |
Volume | 52.64M |
Average Volume | 2.45M |
Market Cap | 622.74M |
PE | -1.72 |
EPS | -5.18 |
Moving Average 50 Days | 4.3 |
Moving Average 200 Days | 9.22 |
Change | 4.23 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $362.6 as of June 07, 2025 at a share price of $8.92. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $163.37 as of June 07, 2025 at a share price of $8.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
GlobeNewswire Inc.
Yesterday at 4:27 PM GMT
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and communicated
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 11:59 AM GMT
New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceu
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing